Navigation Links
NW Bio 2012 Annual Report Shows Strong Progress And Enhancement Of Leadership Position
Date:4/8/2013

ain cancer (which the Company will consider pursuing on a case by case basis if the "Hospital Exemption" is approved).

Progress in DCVax-Direct ProgramThe Company announced its unusually broad Phase I/II clinical trial approved by FDA for DCVax-Direct for all solid tumor cancers.  The Company initiated manufacturing arrangements for this trial in 2012.  The manufacturing involves novel, patented processes for partial maturation of the dendritic cells comprising the active agent of DCVax-Direct, and novel automation with proprietary machines and systems. 

The Company also entered into a Letter of Intent with Sarah Cannon Research Institute to partner in the execution of the Phase I/II trial in the US and UK.  Sarah Cannon has a network of 700 oncology doctors, who see 75,000 new cancer patients per year in the US and UK.

Progress in ManufacturingDue to levels of manufacturing demand significantly higher than originally projected for the Phase III brain cancer trial, the Company arranged for doubling of the manufacturing capacity dedicated to production of DCVax-L in the US.  The Company's contract manufacturer, Cognate BioServices, Inc. (Cognate) undertook the necessary construction for this doubling of capacity.

In Europe, the Company, its partner the Fraunhofer Institute, and Cognate completed the extensive regulatory processes and the final inspections for regulatory approval and certification for the manufacture of DCVax-L for the clinical trial in Germany – processes totaling more than 1-1/2 years of work.  The Company, Fraunhofer, Cognate and Kings College also began the 7-month processes for regulatory approvals and institutional approvals in both the UK and Germany to enable the manufacturing in Germany to supply DCVax-L for the clinical trial in the UK as well.  This German supply arrangement is in addition to the manufacturing under development in the UK.  Having two manufacturing lo
'/>"/>

SOURCE Northwest Biotherapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. DIA 2013 49th Annual Meeting to Address Hot Topics Surrounding Patient Therapies
2. Rosetta Genomics Announces Poster Presentations at AACR Annual Meeting 2013
3. Susan Cain Will Kick Off 2013 ASAE Annual Meeting & Exposition, Dan Heath is Closing General Session Speaker
4. Electronic Headband That Detects and Treats Addictive In-Sleep Behavior to be Demonstrated at Annual Holistic Dental Conference by Holistic Technologies
5. Professional Pricing Society Explores New Role of Pricers as Change Agents and Leaders at 24th Annual Spring Conference
6. Upsher-Smith Presents Favorable Phase I Data For USL261, A Novel Formulation Of Intranasal Midazolam, At 65th Annual Meeting Of The American Academy Of Neurology
7. NW Bio To Review Its Leadership Position In Immune Therapy At The 25th Annual Roth Conference
8. Smith & Nephew hosts thought-leading surgeons, showcases new technology at American Academy of Orthopaedic Surgeons annual meeting
9. Archimedes Inc. Renews Annual Marketing Agreement with HealthEconomics.Com
10. Palatin Technologies To Present At The 25th Annual ROTH Conference
11. Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... RURO, Inc., a leading LIMS, RFID ... version 5.1.4. , RURO’s deployment teams have been ... in RURO’s 8 year history. Many deployments have ... version 5.1.4 is the perfect example – the ... , Limfinity® 5.1.4 release highlights – more than ...
(Date:11/22/2014)... 22, 2014 The “Chiral Chromatography ... by Material (Metal, Glass, Plastic), by Application [GC, ... - Forecast to 2018” analyses and studies the ... North America, Europe, Asia, and Rest of the ... 15 figures spread through 135 pages and in-depth ...
(Date:11/22/2014)... element of surprise has been a major advantage of ... Until now, epidemiologists had nothing to measure that might ... suboptimal responses to both the H1N1 pandemic of 2009 ... http://photos.prnewswire.com/prnh/20141121/160242 That virus advantage ... structural changes have been found that invariably to date ...
(Date:11/21/2014)... , November 21, 2014 , ... comercial   Mariano Rodríguez es elegid vicepresidente ... KLOX está en marcha para comenzar de forma ... de heridas de reciente aprobación en Europa   , ... se complace al anunciar los siguientes nombramientos: ...
Breaking Biology Technology:RURO Announces Limfinity® version 5.1.4 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 3Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 4Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 5Viruses' Advantage of Surprise is Lost 2KLOX Technologies anuncia sus nombramientos ejecutivos 2KLOX Technologies anuncia sus nombramientos ejecutivos 3KLOX Technologies anuncia sus nombramientos ejecutivos 4KLOX Technologies anuncia sus nombramientos ejecutivos 5
... In light of an announcement made recently by Astellas ... confirmed that it had received a letter dated November 13, ... to acquire CV Therapeutics at a price of $16.00 per ... conditions. After careful deliberation, with the assistance of its ...
... quantum dots created by researchers at Canada,s National Institute ... a new level of control over individual electrons, a ... Composed of a single atom of silicon and ... the smallest quantum dots ever created. , ...
... Alfacell Corporation (OTC Bulletin Board: ACEL) today reported that ... Food and Drug Administration (FDA) to discuss the company,s ... rolling New Drug Application (NDA) for the treatment of ... meeting, the FDA provided guidance to the company recommending ...
Cached Biology Technology:CV Therapeutics Statement on Unsolicited Proposal From Astellas 2CV Therapeutics Statement on Unsolicited Proposal From Astellas 3Smallest ever quantum dots bring real world applications closer 2Alfacell Provides ONCONASE(R) NDA Submission Update 2Alfacell Provides ONCONASE(R) NDA Submission Update 3
(Date:11/4/2014)... of Utah engineers developed the first room-temperature fuel cell ... without needing to ignite the fuel. These new fuel ... power and sensors. , A study of the new ... journal ACS Catalysis . , Fuel cells convert ... fuel and an oxygen-rich source such as air. If ...
(Date:11/4/2014)... only marketing directed at children on the interior ... that the majority of black, middle-income and rural ... , Authored by Arizona State University researcher Punam ... first to examine the use of child-directed marketing ... restaurants and its relationship to demographics. It adds ...
(Date:11/3/2014)... 3, 2014 Research and Markets has ... - Technologies, Markets and Companies" to their offering. ... and methods, which have already started to play an important ... is replacing the old fashioned bone marrow transplants. Role of ... bound to become a part of medical practice. ...
Breaking Biology News(10 mins):Jet-fueled electricity at room temperature 2Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3
... the Marine Biological Laboratory (MBL) in Woods Hole and ... the presence of the genetic material RNA in the ... proper cell division. , The findings, detailed June ... Proceedings of the National Academy of Sciences, present evidence ...
... cutting into their yields this year, said two Texas ... Station assistant research scientist and plant disease diagnostician, saw ... Plains Diagnostic Network lab this growing season, in addition ... the Panhandle. , Ninety-five percent of these samples were ...
... either preventing or promoting the cell death, a Queen's University ... principle that pharmacological inhibition of calpain may be used to ... such as in neuronal cells of Alzheimer's or Parkinson's patients, ... is clearly a very desirable outcome," says lead researcher Peter ...
Cached Biology News:RNA found in the cellular centrosome of surf clams 2More than drought affecting wheat yields 2Protein's role in regulating cell death sets direction for cancer research 2
ROCK-1 (cleaved) Monoclonal Ab 100 ug purified mouse monoclonal antibody. Clone# 12M03. Reacts with human. Tested in Western blot analysis....
Mouse monoclonal [LPL4A.1] to Plastin L ( Abpromise for all tested applications). SwissProtID: P13796...
Mouse monoclonal [CAT-1] to Chloramphenicol Acetyltransferase ( Abpromise for all tested applications)....
... Competent Yeast Cells are designed for use ... S. cerevisiae strain MaV203 contains deletions in ... use with GAL4-based two-hybrid systems. The strain ... selection of ProQuest bait and prey vectors. ...
Biology Products: